SG11202002499TA - Combination therapies and uses thereof - Google Patents
Combination therapies and uses thereofInfo
- Publication number
- SG11202002499TA SG11202002499TA SG11202002499TA SG11202002499TA SG11202002499TA SG 11202002499T A SG11202002499T A SG 11202002499TA SG 11202002499T A SG11202002499T A SG 11202002499TA SG 11202002499T A SG11202002499T A SG 11202002499TA SG 11202002499T A SG11202002499T A SG 11202002499TA
- Authority
- SG
- Singapore
- Prior art keywords
- combination therapies
- therapies
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762569239P | 2017-10-06 | 2017-10-06 | |
PCT/US2018/054606 WO2019071123A1 (en) | 2017-10-06 | 2018-10-05 | Combination therapies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202002499TA true SG11202002499TA (en) | 2020-04-29 |
Family
ID=64051695
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202002499TA SG11202002499TA (en) | 2017-10-06 | 2018-10-05 | Combination therapies and uses thereof |
Country Status (17)
Country | Link |
---|---|
US (1) | US11801240B2 (en) |
EP (1) | EP3691685A1 (en) |
JP (1) | JP2020536869A (en) |
KR (1) | KR20200067164A (en) |
CN (1) | CN111182923A (en) |
AU (2) | AU2018346688A1 (en) |
BR (1) | BR112020006845A2 (en) |
CA (1) | CA3076859A1 (en) |
CL (2) | CL2020000907A1 (en) |
CO (1) | CO2020005223A2 (en) |
EA (1) | EA202090655A1 (en) |
IL (1) | IL273510A (en) |
MA (1) | MA50618A (en) |
MX (1) | MX2020003799A (en) |
PH (1) | PH12020550400A1 (en) |
SG (1) | SG11202002499TA (en) |
WO (1) | WO2019071123A1 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI761476B (en) | 2017-03-27 | 2022-04-21 | 美商提薩羅有限公司 | Niraparib compositions |
CN110753684A (en) | 2017-04-24 | 2020-02-04 | 特沙诺有限公司 | Method for producing nilapali |
KR20200005662A (en) | 2017-05-18 | 2020-01-15 | 테사로, 인코포레이티드 | Combination Therapy to Treat Cancer |
SG11202002113TA (en) | 2017-09-26 | 2020-04-29 | Tesaro Inc | Niraparib formulations |
US11661453B2 (en) | 2017-09-30 | 2023-05-30 | Tesaro, Inc. | Combination therapies for treating cancer with niraparib and PD-1 inhibitors |
BR112020006845A2 (en) | 2017-10-06 | 2020-10-06 | Tesaro, Inc. | combined therapies and uses thereof |
CN111093706B (en) * | 2017-12-06 | 2022-06-21 | 江苏恒瑞医药股份有限公司 | Use of PARP inhibitors for the treatment of chemotherapy-resistant ovarian or breast cancer |
WO2020225753A2 (en) | 2019-05-06 | 2020-11-12 | Tesaro, Inc. | Methods for characterizing and treating a cancer type using cancer images |
US20230123585A1 (en) * | 2020-03-03 | 2023-04-20 | The University Of Chicago | Compositions and methods for treating or preventing cancer using deubiquitinase inhibitors |
CN112007042B (en) * | 2020-09-10 | 2023-02-21 | 中国医学科学院医学生物学研究所 | Application of cytarabine and proto-oncoprotein c-FOS inhibitor in preparation of product for treating leukemia |
CN112316149A (en) * | 2020-11-11 | 2021-02-05 | 王海涛 | Medicine for treating TP53 mutant advanced refractory solid tumor and application |
KR20220085742A (en) * | 2020-12-15 | 2022-06-22 | 칸트사이언스 주식회사 | Composition for inhibiting angiogenesis and increasing anticancer treatment effect in cacner patients |
CN114748479B (en) * | 2021-01-08 | 2023-10-20 | 轩竹生物科技股份有限公司 | Pharmaceutical composition for preventing and/or treating cancer |
CN115177621B (en) * | 2021-04-02 | 2023-09-01 | 上海市第一人民医院 | Application of AV-951 in preparation of drugs for inhibiting or treating thyroid-related eye diseases |
CN113101288A (en) * | 2021-05-08 | 2021-07-13 | 中国人民解放军空军军医大学 | Combined medicine for synergistically treating chordoma and application thereof |
CN114712515A (en) * | 2022-03-30 | 2022-07-08 | 上海交通大学医学院附属瑞金医院 | Application of DLL4 inhibitor and PARP inhibitor in preparation of medicine for treating ovarian cancer |
CN115177594B (en) * | 2022-07-04 | 2023-08-15 | 武汉大学中南医院 | Acetinib pharmaceutical preparation and preparation method thereof |
CN115154589B (en) * | 2022-08-26 | 2024-04-09 | 山东大学 | Application of resveratrol combined with fibroblast growth factor 1 in relieving anthracycline-induced heart and liver toxicity |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2806454B2 (en) | 1988-01-19 | 1998-09-30 | 武田薬品工業株式会社 | Angiogenesis inhibitor |
KR0141692B1 (en) | 1988-09-01 | 1998-06-01 | 우메모또 요시마사 | Angiogenesis inhibitory agent |
PT1537878E (en) | 2002-07-03 | 2010-11-18 | Ono Pharmaceutical Co | Immunopotentiating compositions |
US9707302B2 (en) | 2013-07-23 | 2017-07-18 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
JP4611441B2 (en) | 2006-04-03 | 2011-01-12 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | Amide-substituted indazole and benzotriazole derivatives as poly (ADP-ribose) polymerase (PARP) inhibitors |
JP4611444B2 (en) | 2007-01-10 | 2011-01-12 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | Amide substituted indazoles as poly (ADP-ribose) polymerase (PARP) inhibitors |
DK2170959T3 (en) | 2007-06-18 | 2014-01-13 | Merck Sharp & Dohme | ANTIBODIES AGAINST HUMAN PROGRAMMED DEATH RECEPTOR PD-1 |
KR20100102609A (en) | 2007-11-12 | 2010-09-24 | 바이파 사이언스 인코포레이티드 | Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents |
SG185954A1 (en) * | 2007-11-12 | 2012-12-28 | Bipar Sciences Inc | Treatment of ovarian cancer with 4-iodo-3-nitrobenzamide in combination with anti-tumor agents |
EP2237684A2 (en) | 2008-01-08 | 2010-10-13 | Akthelia Pharmaceuticals | Agonists for antimicrobial peptide systems |
CA2711491C (en) | 2008-01-08 | 2016-03-08 | Jennifer R. Foley | Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide |
TWI686405B (en) | 2008-12-09 | 2020-03-01 | 建南德克公司 | Anti-pd-l1 antibodies and their use to enhance t-cell function |
KR20110113648A (en) | 2009-02-04 | 2011-10-17 | 바이파 사이언스 인코포레이티드 | Treatment of lung cancer with a parp inhibitor in combination with a growth factor inhibitor |
KR101790767B1 (en) | 2009-11-24 | 2017-10-26 | 메디뮨 리미티드 | Targeted binding agents against b7-h1 |
WO2011153383A1 (en) | 2010-06-04 | 2011-12-08 | Bipar Science, Inc. | Methods of treating platinum-resistant recurrent ovarian cancer with 4-iodo-3-nitrobenzamide in combination with an anti-metabolite and a platinum compound |
EP2582847B1 (en) | 2010-06-18 | 2016-10-26 | Myriad Genetics, Inc. | Methods and materials for assessing loss of heterozygosity |
NZ606725A (en) | 2010-08-24 | 2014-06-27 | Dana Farber Cancer Inst Inc | Methods for predicting anti-cancer response |
CA2742342A1 (en) | 2011-02-12 | 2012-08-12 | Baylor Research Institute | Msh3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with parp inhibitors and platinum drugs |
DK2785375T3 (en) | 2011-11-28 | 2020-10-12 | Merck Patent Gmbh | ANTI-PD-L1 ANTIBODIES AND USES THEREOF |
NZ630278A (en) | 2012-06-07 | 2017-02-24 | Inst Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
WO2014088984A1 (en) | 2012-12-07 | 2014-06-12 | Merck Sharp & Dohme Corp. | Biocatalytic transamination process |
WO2014088983A1 (en) | 2012-12-07 | 2014-06-12 | Merck Sharp & Dohme Corp. | Regioselective n-2 arylation of indazoles |
WO2014138101A1 (en) | 2013-03-04 | 2014-09-12 | Board Of Regents, The University Of Texas System | Gene signature to predict homologous recombination (hr) deficient cancer |
AR095363A1 (en) | 2013-03-15 | 2015-10-14 | Genentech Inc | BIOMARKERS AND METHODS FOR THE TREATMENT OF CONDITIONS RELATED TO PD-1 AND PD-L1 |
RS61400B1 (en) | 2013-05-02 | 2021-02-26 | Anaptysbio Inc | Antibodies directed against programmed death-1 (pd-1) |
EP3080292B1 (en) | 2013-12-09 | 2022-02-02 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
EP3094752A4 (en) | 2014-01-16 | 2017-08-16 | Clovis Oncology, Inc. | Use of parp inhibitors to treat breast or ovarian cancer patients showing a loss of heterozygosity |
US20170175197A1 (en) | 2014-01-29 | 2017-06-22 | Caris Mpi, Inc. | Molecular profiling of immune modulators |
EP3148336B1 (en) | 2014-05-28 | 2019-10-02 | Eisai R&D Management Co., Ltd. | Eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer |
US20150344968A1 (en) | 2014-05-30 | 2015-12-03 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Methods for determining parp inhibitor and platinum resistance in cancer therapy |
EP3230472A4 (en) | 2014-12-08 | 2018-06-13 | Myriad Genetics, Inc. | Methods and materials for predicting response to niraparib |
MA41463A (en) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | ANTIBODIES DIRECTED AGAINST LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) |
MA41867A (en) | 2015-04-01 | 2018-02-06 | Anaptysbio Inc | T-CELL IMMUNOGLOBULIN AND MUCINE PROTEIN 3 ANTIBODIES (TIM-3) |
US10174113B2 (en) | 2015-04-28 | 2019-01-08 | Bristol-Myers Squibb Company | Treatment of PD-L1-negative melanoma using an anti-PD-1 antibody and an anti-CTLA-4 antibody |
US20170000885A1 (en) | 2015-06-08 | 2017-01-05 | Genentech, Inc. | Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists |
PL3313443T3 (en) | 2015-06-25 | 2023-11-06 | Immunomedics, Inc. | Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
SG10201913073YA (en) | 2015-08-20 | 2020-03-30 | Ipsen Biopharm Ltd | Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment |
US20190054087A1 (en) | 2015-10-26 | 2019-02-21 | Medivation Technologies Llc | Treatment of small cell lung cancer with a parp inhibitor |
TWI827530B (en) * | 2016-02-15 | 2024-01-01 | 瑞典商阿斯特捷利康公司 | Methods comprising fixed intermittent dosing of cediranib |
CN109640992A (en) | 2016-06-29 | 2019-04-16 | 泰萨罗公司 | The method for treating oophoroma |
US11202782B2 (en) | 2016-09-27 | 2021-12-21 | Beigene, Ltd. | Treatment cancers using a combination comprising PARP inhibitors |
KR20190101364A (en) | 2016-11-01 | 2019-08-30 | 테사로, 인코포레이티드 | Antibody Against Probable Death-1 (PD-1) |
KR20190098741A (en) | 2016-11-01 | 2019-08-22 | 아납티스바이오, 아이엔씨. | Antibodies to T Cell Immunoglobulins and Mucin Protein 3 (TIM-3) |
US11926665B2 (en) | 2017-01-09 | 2024-03-12 | Tesaro, Inc. | Methods of treating cancer with anti-TIM-3 antibodies |
US11407830B2 (en) | 2017-01-09 | 2022-08-09 | Tesaro, Inc. | Methods of treating cancer with anti-PD-1 antibodies |
CN110709083A (en) | 2017-03-27 | 2020-01-17 | 特沙诺有限公司 | Nilaparib formulations |
TWI761476B (en) | 2017-03-27 | 2022-04-21 | 美商提薩羅有限公司 | Niraparib compositions |
CN110753684A (en) | 2017-04-24 | 2020-02-04 | 特沙诺有限公司 | Method for producing nilapali |
CA3059468A1 (en) | 2017-04-27 | 2018-11-01 | Tesaro, Inc. | Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof |
MA48637A (en) | 2017-05-09 | 2021-03-17 | Merck Sharp & Dohme | POLYTHERAPIES FOR THE TREATMENT OF CANCER |
KR20200005662A (en) | 2017-05-18 | 2020-01-15 | 테사로, 인코포레이티드 | Combination Therapy to Treat Cancer |
US20200129482A1 (en) | 2017-06-26 | 2020-04-30 | Abbvie Inc. | Treatment of non-small cell lung cancer |
SG11202002113TA (en) | 2017-09-26 | 2020-04-29 | Tesaro Inc | Niraparib formulations |
US11661453B2 (en) | 2017-09-30 | 2023-05-30 | Tesaro, Inc. | Combination therapies for treating cancer with niraparib and PD-1 inhibitors |
BR112020006845A2 (en) | 2017-10-06 | 2020-10-06 | Tesaro, Inc. | combined therapies and uses thereof |
BR112020013214A2 (en) | 2017-12-27 | 2020-12-01 | Tesaro, Inc. | methods to treat cancer |
SG11202007420PA (en) | 2018-02-05 | 2020-09-29 | Tesaro Inc | Pediatric niraparib formulations and pediatric treatment methods |
EA201992594A1 (en) | 2018-03-26 | 2020-03-20 | Тесаро, Инк. | COMBINED THERAPIES FOR TREATMENT OF CANCER |
US20220048983A1 (en) | 2020-08-13 | 2022-02-17 | Astrazeneca Ab | Methods of treating homologous recombination deficient cancer |
-
2018
- 2018-10-05 BR BR112020006845-4A patent/BR112020006845A2/en not_active Application Discontinuation
- 2018-10-05 WO PCT/US2018/054606 patent/WO2019071123A1/en unknown
- 2018-10-05 JP JP2020519286A patent/JP2020536869A/en active Pending
- 2018-10-05 AU AU2018346688A patent/AU2018346688A1/en not_active Abandoned
- 2018-10-05 US US16/754,083 patent/US11801240B2/en active Active
- 2018-10-05 MA MA050618A patent/MA50618A/en unknown
- 2018-10-05 CA CA3076859A patent/CA3076859A1/en active Pending
- 2018-10-05 SG SG11202002499TA patent/SG11202002499TA/en unknown
- 2018-10-05 KR KR1020207012376A patent/KR20200067164A/en not_active Application Discontinuation
- 2018-10-05 EA EA202090655A patent/EA202090655A1/en unknown
- 2018-10-05 CN CN201880065336.2A patent/CN111182923A/en active Pending
- 2018-10-05 EP EP18796190.9A patent/EP3691685A1/en not_active Withdrawn
- 2018-10-05 MX MX2020003799A patent/MX2020003799A/en unknown
-
2020
- 2020-03-23 IL IL273510A patent/IL273510A/en unknown
- 2020-04-03 PH PH12020550400A patent/PH12020550400A1/en unknown
- 2020-04-03 CL CL2020000907A patent/CL2020000907A1/en unknown
- 2020-04-27 CO CONC2020/0005223A patent/CO2020005223A2/en unknown
- 2020-11-13 CL CL2020002958A patent/CL2020002958A1/en unknown
-
2022
- 2022-03-21 AU AU2022201944A patent/AU2022201944A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CO2020005223A2 (en) | 2020-05-15 |
JP2020536869A (en) | 2020-12-17 |
AU2022201944A1 (en) | 2022-04-14 |
IL273510A (en) | 2020-05-31 |
KR20200067164A (en) | 2020-06-11 |
PH12020550400A1 (en) | 2021-03-08 |
WO2019071123A1 (en) | 2019-04-11 |
US20200306236A1 (en) | 2020-10-01 |
US11801240B2 (en) | 2023-10-31 |
CL2020000907A1 (en) | 2020-08-14 |
MA50618A (en) | 2020-08-12 |
CN111182923A (en) | 2020-05-19 |
EP3691685A1 (en) | 2020-08-12 |
MX2020003799A (en) | 2020-11-06 |
CA3076859A1 (en) | 2019-04-11 |
BR112020006845A2 (en) | 2020-10-06 |
EA202090655A1 (en) | 2020-12-07 |
CL2020002958A1 (en) | 2021-03-05 |
AU2018346688A1 (en) | 2020-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL273510A (en) | Combination therapies and uses thereof | |
ZA202002184B (en) | Adenovirus and uses thereof | |
ZA202002191B (en) | Adenovirus and uses thereof | |
IL274407A (en) | Combination therapies | |
HK1243741A1 (en) | Tnfrsf-binding agents and uses thereof | |
IL255577B (en) | Tigit-binding agents and uses thereof | |
IL293377A (en) | Hsd17b13 variants and uses thereof | |
IL264813B (en) | 2-oxo-imidazopyridines and their use | |
IL274220A (en) | Adenovirus and uses thereof | |
HK1247122A1 (en) | Combinations and uses thereof | |
IL254241A0 (en) | Etv2 and uses thereof | |
IL265531A (en) | N 3 -cyclically substituted thienouraciles and use thereof | |
IL264473A (en) | Gpr156 variants and uses thereof | |
GB2584009B (en) | Aminoglycosides and uses thereof | |
IL275211A (en) | Fast and partition-resilient blockchains | |
IL269836B (en) | Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof | |
IL269843B (en) | Substituted n-arylethyl-2-arylquinoline-4-carboxamides and use thereof | |
GB201508028D0 (en) | Sandfalls and the like | |
IL271555A (en) | Combination and uses and treatments thereof | |
GB201707279D0 (en) | Multiearphones and polyearphones | |
GB2545167B (en) | Cloches and use thereof | |
ZA201507311B (en) | Hinge arrangement and device comprising the arrangement | |
GB201500278D0 (en) | Novel combination and use |